Key Developments: Merck & Co Inc (MRK)

MRK on New York Consolidated

2 Oct 2015
Change (% chg)

$0.77 (+1.56%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Plexxikon and Merck to collaborate on combination study evaluating investigational immuno-oncology regimen
Thursday, 7 May 2015 08:30am EDT 

Plexxikon Inc and Merck & Co Inc:Says collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikon's investigational CSF-1R inhibitor, and KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, which provides the potential for double blockade of cancer-induced immune suppression.The Phase 1/2 trial will enroll patients with advanced melanoma and multiple other solid tumors with the goal of determining the safety and tolerability of the combination therapy.The trial is expected to begin enrollment by mid-year.  Full Article

Merck & Co Inc reaffirms FY 2015 guidance, raises EPS outlook
Tuesday, 28 Apr 2015 07:07am EDT 

Merck & Co Inc:Continues to expect FY 2015 revenues to be between $38.3 and $39.8 billion, including a $2.8 billion negative impact from foreign exchange and about $1 billion of net lost sales from acquisitions and divestitures.Now expects FY 2015 non-GAAP EPS that excludes items between $3.35 to $3.48.FY 2015 revenue of $39.2 bln and EPS of $3.37 - Thomson Reuters I/B/E/S.  Full Article

Merck announces publication of pivotal data from phase 3 clinical studies of ZERBAXA
Monday, 27 Apr 2015 06:30pm EDT 

Merck:Says The Lancet and Clinical Infectious Diseases have published online the results from the pivotal Phase 3 clinical studies of ZERBAXA (ceftolozane/tazobactam) for Injection (1 g/0.5 g) in complicated urinary tract infections and complicated intra-abdominal infections (cIAI), respectively.Says results will also appear in forthcoming print issues of the journals.Merck acquired ZERBAXA as a part of its purchase of Cubist Pharmaceuticals, Inc.Publications report the results of two large, global, Phase 3 clinical studies of ZERBAXA - a study in patients with cUTI and a study in patients with cIAI.Both studies met the pre-specified primary endpoints, and results of the secondary analyses for the studies were consistent with and supportive of the primary outcomes.  Full Article

China Animal Husbandry Industry signs MOU with subsidiary of Merck & Co., Inc
Thursday, 26 Mar 2015 08:00pm EDT 

China Animal Husbandry Industry Co Ltd:Signed MOU (Memorandum of Understanding) with Intervet Holding BV, wholly owned subsidiary of Merck & Co., Inc., to cooperate on domestic market development.  Full Article

Ablynx NV announces extension of ion channel research collaboration with Merck & Co., Inc
Thursday, 26 Mar 2015 02:10am EDT 

Ablynx NV:Announces an extension of its initial two-year research collaboration with Merck & Co., Inc., known as MSD outside the United States and Canada, to develop and commercialise Nanobody candidates directed towards an undisclosed voltage gated ion channel.Says Merck & Co., Inc. will extend their funding of the research collaboration with Ablynx to the end of Sept. 2016.Says this ion channel collaboration was announced in Oct. 2012 and included a EUR6.5 million upfront payment and EUR2 million in initial research funding.  Full Article

Merck & Co Inc announces new $10 billion share repurchase program
Tuesday, 24 Mar 2015 05:00pm EDT 

Merck & Co Inc:Authorizes additional purchases of up to $10 billion of common stock for its treasury.Says treasury stock purchase has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions.  Full Article

Merck & Co Inc's pivotal keynote-006 study in first-line treatment for advanced melanoma met co-primary endpoints and will be stopped early
Tuesday, 24 Mar 2015 08:30am EDT 

Merck & Co Inc:Announced that the randomized, pivotal Phase 3 study (KEYNOTE-006) investigating KEYTRUDA compared to ipilimumab in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival and overall survival.Says the trial will be stopped early based on the recommendation of the study's independent Data Monitoring Committee.In KEYNOTE-006, KEYTRUDA demonstrated a statistically and clinically meaningful improvement in overall survival and progression-free survival compared to ipilimumab.Says the safety profile of KEYTRUDA in this trial was similar to the safety profile previously reported in advanced melanoma.KEYTRUDA is the first anti-PD-1 therapy to demonstrate a survival advantage compared to the standard of care for the first-line treatment of advanced melanoma.These data will be presented in the opening plenary session at the American Association of Cancer Research (AACR) Annual Meeting in Philadelphia, April 18-22.  Full Article

Merck announces second-quarter 2015 dividend
Tuesday, 24 Feb 2015 12:51pm EST 

Merck:Declares a quarterly dividend of $0.45 per share of the company's common stock for the second quarter of 2015.Payment will be made on Apr. 8 to stockholders of record at the close of business on Mar. 16.  Full Article

Merck & Co Inc announces collaboration with the Medicines Patent Pool
Tuesday, 24 Feb 2015 03:00am EST 

Merck & Co Inc:Announces an agreement with Medicines Patent Pool to license its pediatric formulations of raltegravir for use in treating HIV-1 infection in infants and children from four weeks to under 12 years of age in developing countries.  Full Article

NGM and Merck announces broad strategic collaboration to discover, develop and commercialize novel biologic therapeutics
Monday, 23 Feb 2015 07:00am EST 

Merck:NGM Biopharmaceuticals, Inc.,and Merck announceS they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas.This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis (NASH).Under the terms of the agreement, Merck will make an upfront payment to NGM of $94 million and will purchase a 15 percent equity stake in NGM for $106 million at price per share that represents a 20 percent premium to NGM's most recent financing.Merck will commit up to $250 million to fund all of NGM's efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met.  Full Article


FDA expands approval of Merck's Keytruda to lung cancer

- The U.S. Food and Drug Administration on Friday approved Merck & Co Inc's immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker.

Search Stocks